Indications
Prescribing Information

Learn how to Use
Biocon’s Liraglutide Injection

Two easy ways to learn how to prepare and inject Biocon’s Liraglutide Injection.

Watch the Instructions for Use (IFU) video. If you prefer step-by-step written guidance, download the IFU document.

Your healthcare provider will demonstrate the correct way to use Biocon’s Liraglutide Injection. Use it exactly as your healthcare provider instructs.

Do not use your pen without proper training from your healthcare provider. Make sure you know how to give yourself an injection before you start treatment.

How to use Biocon’s Liraglutide Injection

FPO

Click here for Instructions for Use.

Download IFU document
Scroll to Top

You are now departing from the Liraglutide Type 2 Diabetes patient website and redirected to the Biocon Biologics corporate website. Please be aware that the Biocon Biologics corporate website may contain information that varies from the content on the Liraglutide Type 2 Diabetes patient website. The website you are about to access is the corporate website located outside of the U.S.
U.S. regulations may not be applicable to the content on this corporate website.

OK
CANCEL

INDICATIONS

Liraglutide injection is an injectable prescription medicine used:

  • Along with diet and exercise to improve blood sugar (glucose) in adults and children who are 10 years of age and older with  type 2 diabetes mellitus.
  • To reduce the risk of major cardiovascular events such as heart attack, stroke or death in adults with type 2 diabetes mellitus with known heart disease.
  • Liraglutide injection is not recommended for people who take liraglutide or other medicines called glucagon-like peptide-1 (GLP-1) receptor agonists.
  • It is not known if liraglutide injection is safe and effective to lower blood sugar (glucose) in children under 10 years of age.

You are now leaving the liraglutide type 2 diabetes patient website. Liraglutide injection is a prescription medicine indicated as an adjunct to diet and exercise to improve blood sugar (glucose) in adults and pediatric patients aged 10 years and older with type 2 diabetes mellitus, and to reduce the risk of major adverse cardiovascular events in adults with type 2 diabetes mellitus and established cardiovascular disease.

Biocon Limited Inc. assumes no responsibility for and makes no warranties or representation of any kind as to the accuracy, currency, or completeness of any information contained in such third-party website, including any third-party social media or mobile application platform. Inclusion of any third-party link on this website does not imply an endorsement or recommendation by Biocon Limited, and a link to this website from another website does not imply a relationship between Biocon Limited and any third party. Your use of any such third-party site or platform is at your own risk and will be governed by such third party’s terms and policies (including its privacy policy). Biocon Limited shall not be liable for any direct, indirect, consequential, incidental or punitive damages arising out of access to, use of, or inability to use such third-party website, or any errors or omissions in the content thereof.

OK
CANCEL